The objective of this application is to define the leadership and operational structures for the Microbicide Trials Network (MTN). The MTN was first established in 2006 to identify a safe and effective microbicide for HIV prevention. From the outset, the MTN targeted key populations at risk of HIV including women in Sub- Saharan Africa, adolescents, pregnant and lactating women, and MSM. Over the last six years, the MTN has developed an expansive program in vaginal and rectal microbicide development, with unique and substantial contributions to the field in the understanding of the safety, effectiveness, pharmacokinetics, and the behavioral context associated with the use of topical microbicides. Since its inception, it has developed a total of 31 new protocols. The proposed plan in this continuing application is to build on this foundation of research to expand the portfolio of active agents to be tested in phase 1-3 studies over the next 7 years. It is anticipated that these studies will build toward a phase 2B/3 studies of a rectal microbicide and a combination antiretroviral/hormonal contraceptive ring. Cutting edge biomedical and behavioral research approaches will be incorporated through the contributions of the biomedical and behavioral research working groups, and community perspectives on protocols will be incorporated through the community working group.
Microbicides are new drug products which are being developed for use by people for prevention of HIV infection. This grant application describes a leadership structure for the Microbicide Trials Network, a clinical trials network whose purpose is to develop microbicide products from the early stages of product development through final approval by regulatory authorities.
|Balkus, Jennifer E; Palanee-Phillips, Thesla; Reddy, Krishnaveni et al. (2017) Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception. J Acquir Immune Defic Syndr 76:e47-e51|
|Montgomery, Elizabeth T; van der Straten, Ariane; Chitukuta, Miria et al. (2017) ""It's inside my body and it's mine"". AIDS :|
|Giguere, Rebecca; Rael, Christine Tagliaferri; Sheinfil, Alan et al. (2017) Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial. AIDS Behav :|
|Montgomery, Elizabeth T; Mensch, B; Musara, P et al. (2017) Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty. AIDS Behav 21:481-491|
|Livant, Edward; Heaps, Amy; Kelly, Cliff et al. (2017) The fourth generation AlereTM HIV Combo rapid test improves detection of acute infection in MTN-003 (VOICE) samples. J Clin Virol 94:15-21|
|Carballo-Diéguez, Alex; Balán, Ivan C; Brown 3rd, William et al. (2017) High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. PLoS One 12:e0181607|
|Cosentino, Lisa A; Danby, Claire S; Rabe, Lorna K et al. (2017) Use of Nucleic Acid Amplification Testing for Diagnosis of Extragenital Sexually Transmitted Infections. J Clin Microbiol 55:2801-2807|
|Koss, Catherine A; Bacchetti, Peter; Hillier, Sharon L et al. (2017) Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS Res Hum Retroviruses :|
|DeMarco, Allison L; Rabe, Lorna K; Austin, Michele N et al. (2017) Survival of vaginal microorganisms in three commercially available transport systems. Anaerobe 45:44-49|
|Richardson-Harman, Nicola; Parody, Robert; Anton, Peter et al. (2017) Analytical Advances in the Ex Vivo Challenge Efficacy Assay. AIDS Res Hum Retroviruses 33:395-403|
Showing the most recent 10 out of 102 publications